MedTrace Logo

Radioactive Holmium Microspheres for the Treatment of Liver Metastases

NCT01031784 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2012-01-31

No results posted yet for this study

Summary

The HEPAR study is aimed at determining the safety of radioactive holmium containing microspheres for the treatment of tumors in the liver. These microspheres will be administered by infusion in the liver artery using a arterial catheter in the femoral artery.

Conditions

  • Liver Metastasis
  • Liver Tumors

Interventions

DEVICE

holmium-166 poly lactic acid microspheres

Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose

DEVICE

holmium 166 microspheres

intra arterial administration of holmium 166 microsphers in the hepatic artery

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Bernard Zonnenberg, MD, Ph.D · UMC Utrecht

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01031784 on ClinicalTrials.gov